Aktietilbagekøbsprogram i SP Group A/S
Den 11. april 2022 igangsatte SP Group A/S (SPG) et aktietilbagekøbsprogram jf. selskabsmeddelelse nr. 18/2022 af 25. marts 2022.
Ved aktietilbagekøbsprogrammet, som løber i perioden fra den 11. april 2022 til og med den 10. april 2023, vil SPG købe aktier for et maksimalt vederlag på DKK 40,0 mio.
Aktietilbagekøbsprogrammet blev iværksat efter bestemmelserne i EU-kommissionens forordning nr. 596/2014 af den 16. april 2014 om markedsmisbrug, den såkaldte ’markedsmisbrugsforordning’, som værner børsnoterede selskabers bestyrelse og direktion imod overtrædelse af insiderlovgivningen i forbindelse med aktietilbagekøb.
Vedhæftet fil
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons19.4.2024 17:05:00 CEST | Press release
Company announcement – No. 23 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and
Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 202419.4.2024 17:00:00 CEST | Press release
Company announcement – No. 22 / 2024 Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the implementation of long-term incentive programs (the “LTIP”) for Zealand's Board of Directors, Corporate Management and employees in accordance with Zealand's remuneration policy and overall guidelines for incentive pay, as adopted at the annual general meeting held on March 20, 2024 (“Remuneration Policy”). Long-term incentive program Zealand has made the following awards in its long-term incentive plan. It has awarded: 20,497 restricted stock units ("RSUs") to Zealand's Board of Directors 52,777 performance stock units ("PSUs") and 52,777 RSUs have been awarded to Zealand’s Corporat
Dr. Sam Barrell CBE appointed as CEO of LifeArc19.4.2024 17:00:00 CEST | Press release
PRESS RELEASE FOR IMMEDIATE PUBLICATION 19 April 2024 Dr. Sam Barrell CBE appointed as CEO of LifeArc LifeArc is pleased to announce the appointment of Dr. Sam Barrell, CBE, as Chief Executive Officer. Sam’s appointment follows an extensive international recruitment process. Sam will join LifeArc from the Francis Crick Institute where she is currently Deputy CEO with responsibility for strategic management and operational leadership, as well as deputising for the Director, Sir Paul Nurse. She joined the Crick in 2017 as Chief Operating Officer. Sam brings over 25 years of experience in the life science and healthcare sectors, and a wealth of knowledge of the activities in commercial, digital and health tech spaces which are critical to LifeArc’s strategy. She studied medicine, training as an anaesthetist and serving in General Practice for many years, and has held a number of senior leadership positions in the NHS, most recently as CEO of Taunton and Somerset NHS Foundation Trust. She
EMGS – Annual report for 2023 - ESEF19.4.2024 17:00:00 CEST | Press release
Reference is made to the stock exchange notice published by Electromagnetic Geoservices ASA ("EMGS" or the "Company") on 17 April 2024, where EMGS published its audited financial statements and annual report for 2023. As noted by the Company in that stock exchange notification, the European Single Electronic Format (ESEF) 2023 annual report would be published on or about 19 April 2024. The ESEF file is attached to this stock exchange notification and will also be available on www.emgs.com. Contact Anders Eimstad, Chief Financial Officer, +47 948 25 836 This information is published in accordance with the Norwegian Securities Trading Act § 5-12. About EMGS EMGS, the marine EM market leader, uses its proprietary electromagnetic (EM) technology to support oil and gas companies in their search for offshore hydrocarbons. EMGS supports each stage in the workflow, from survey design and data acquisition to processing and interpretation. The Company's services enable the integration of EM data
SFL - Notice of exercise of call option19.4.2024 16:50:02 CEST | Press release
SFL Corporation Ltd. (NYSE: SFL) ("SFL" or the "Company") has today notified Nordic Trustee AS that it will exercise the call option to redeem all outstanding bonds under its senior secured bond issue 2019/2024 with ISIN NO0010853609. Reference is made to the attached notice from Nordic Trustee AS for further information about the call option. April 19, 2024 The Board of Directors SFL Corporation Ltd. Hamilton, Bermuda Investor and Analyst Contacts: Aksel Olesen, Chief Financial Officer, SFL Management AS +47 23 11 40 36 André Reppen, Chief Treasurer & Senior Vice President, SFL Management AS +47 23 11 40 55 Sander Borgli, Vice President - IR, SFL Management AS +47 23 11 40 73 Media Contact: Ole B. Hjertaker, Chief Executive Officer, SFL Management AS +47 23 11 40 11 About SFL SFL has a unique track record in the maritime industry and has paid dividends every quarter since its initial listing on the New York Stock Exchange in 2004. The Company’s fleet of vessels is comprised of tanker